Mirko M. Essing

1 ta ish

Neovii Biotech (Germany)

1. Humoral response to catumaxomab correlates with clinical outcome: Results of the pivotal phase II/III study in patients with malignant ascites

   Marion Ott, Frederik Marmé, Gerhard Moldenhauer +6

   Maqola20112 iqtibos

   ABIABI:AkademIndex/2026.other.913711